Literature DB >> 28627218

Performance evaluation of three platforms with ultrasensitive ligand-binding assay potential.

Kyra Juliana Cowan1, Albert Geiger2, Hans Hornauer2, Robyn Rourick1, Patricia Yanira Siguenza1.   

Abstract

AIM: We evaluated three immunoassay-based technologies and their biomarker kits, by determining precision, parallelism and detectability of analytes of interest. MATERIALS &
METHODS: We compared ultrasensitive assays for three biomarkers: interleukins IL-6, IL-13 and IL-17A using kits obtained from Roche (IMPACT platform - proprietary platform), Singulex (Erenna®) and Quanterix (Simoa™). We defined the true LLOD as the LLOQs, and provided disease-specific parallelism results and detectability levels for endogenous analyte, which were good across platforms, though they varied from analyte to analyte.
CONCLUSION: We highlight a simplified approach employed for evaluating ultrasensitive kits and provide an overview of the methodologies used to compare available assays. All three platforms are able to detect very low-level analytes. We recommend all three platforms for detection of very low-level analytes.

Entities:  

Keywords:  biomarker; immunoassay; ligand-binding assay; parallelism; platform comparison; ultrasensitive

Mesh:

Substances:

Year:  2017        PMID: 28627218     DOI: 10.4155/bio-2017-0024

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  1 in total

1.  A Multi-site In-depth Evaluation of the Quanterix Simoa from a User's Perspective.

Authors:  Allison Given Chunyk; Alison Joyce; Saloumeh K Fischer; Mark Dysinger; Alvydas Mikulskis; Andreas Jeromin; Rosemary Lawrence-Henderson; Dana Baker; David Yeung
Journal:  AAPS J       Date:  2017-12-01       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.